Please provide your email address to receive an email when new articles are posted on . The FDA plans to reduce and potentially replace animal testing for developing monoclonal antibody therapies and ...
The Food and Drug Administration (FDA) announced Thursday it plans to phase out animal testing requirements for biological products and drugs, instead moving toward alternative testing models such ...
Morning Overview on MSN
FDA urges alternatives to animal testing in early-stage drug development
The U.S. Food and Drug Administration is actively steering drug developers away from traditional animal studies and toward ...
Resource explains ISO 17025 requirements, how to verify accreditation in A2LA & ANAB directories, and why scope ...
The FDA has released draft guidance aimed at helping drug developers shift away from traditional animal testing as the ...
Organoids, organs-on-a-chip, and machine learning technologies have improved dramatically in recent years, but have they come far enough to replace animal research? Additionally, despite attempts to ...
Several stocks in the health care technology space are moving higher after the market close on Thursday after the U.S. Food and Drug Administration (FDA) announced plans to phase out animal testing ...
In April 2025, the FDA announced plans to shift biomedical research for monoclonal antibodies and other medications away from ...
The FDA is doubling down on its goal to increase biosimilar drug availability in the U.S. with a fresh draft guidance proposing more changes to streamline development of the cheaper biologic copies.
A federal district court has struck a blow for medical innovation and patient empowerment by overruling the Food and Drug Administration's (FDA) misbegotten effort to regulate laboratory-developed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results